Japan’s Chugai Forecasts Record-Setting Profit Decline In 2008
This article was originally published in PharmAsia News
Chugai Pharmaceutical of Japan, a Roche Holding subsidiary, expects its profits this year to decline more than in any year in its 24-year history, the company reported. The company cited lower drug prices ordered by the government and drops in sales of its three best-selling drugs. Chugai also voluntarily lowered the price of its best-selling Epogin last July in an effort to compete with Kirin Holdings' competing product. (Click here for more
You may also be interested in...
Regulatory pressure to fully approve the first COVID-19 vaccine in China is mounting as top officials tour an inspection agency and two leading manufacturers.
A proposed rule released last month by the US Department of Health and Human Services is the Trump administration’s “latest attempt to sabotage HHS programs,” wrote Jessica Schubel, a senior policy analyst for the Center on Budget and Policy Priorities. See what the policy expert said about it in her blog post here.
Helped by a hefty financing earlier this year, Bukwang subsidiary Contera Pharma is poised to speed ongoing multinational Phase II trials with its lead asset for Parkinson’s-associated dyskinesia by hiring CNS experts as new top executives, as the Korean firm looks to take it public in ground-breaking move.